Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy

Objectives. To describe the clinical characteristics of patients presenting with fulminant liver failure after varying periods of exposure to Efavirenz containing antiretroviral medications. Methods. We report a series of 4 patients with human immunodeficiency virus (HIV) infection who were admitted...

Full description

Saved in:
Bibliographic Details
Main Authors: Innocent Lule Segamwenge, Miriam Kaunanele Bernard
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Case Reports in Hepatology
Online Access:http://dx.doi.org/10.1155/2018/1270716
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552837988483072
author Innocent Lule Segamwenge
Miriam Kaunanele Bernard
author_facet Innocent Lule Segamwenge
Miriam Kaunanele Bernard
author_sort Innocent Lule Segamwenge
collection DOAJ
description Objectives. To describe the clinical characteristics of patients presenting with fulminant liver failure after varying periods of exposure to Efavirenz containing antiretroviral medications. Methods. We report a series of 4 patients with human immunodeficiency virus (HIV) infection who were admitted with acute liver failure (ALF) over a 6-month period. All these patients had been treated with a range of Efavirenz containing antiretroviral regimens and were negative for hepatitis A, B, and C infections as well as other opportunistic infections, all were negative for autoimmune hepatitis, and none had evidence of chronic liver disease or use of alcohol or herbal medications. Information on patient clinical characteristics, current antiretroviral regimen, CD4 count, HIV-1 RNA levels, and clinical chemistry parameters was collected. Informed consent was provided. Results. During a 6-month period, four patients without other known risk factors for acute hepatitis presented with symptomatic drug-induced liver injury with varying symptoms and outcomes. The pattern of liver injury was hepatocellular for all the 4 cases. Liver biopsies were done for all the four cases and the results showed a heavy mixed inflammatory cell infiltrate with eosinophils. For three patients withdrawal of Efavirenz from their antiretroviral regimen was sufficient to restore transaminase levels to normal and led to improvement of clinical symptoms. For one patient his clinical course was characterized by fulminant liver failure and fluctuating episodes of hepatic encephalopathy which ultimately resulted in his death. Conclusion. Hepatotoxicity of Efavirenz is not as rare as previously described in the literature and does actually present with fatal outcomes. The key message to note is that frequent monitoring of liver enzymes should be done at initiation of antiretroviral therapy and should continue throughout the treatment period.
format Article
id doaj-art-30d655e667b541928eb271adc61b5485
institution Kabale University
issn 2090-6587
2090-6595
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Case Reports in Hepatology
spelling doaj-art-30d655e667b541928eb271adc61b54852025-02-03T05:57:42ZengWileyCase Reports in Hepatology2090-65872090-65952018-01-01201810.1155/2018/12707161270716Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral TherapyInnocent Lule Segamwenge0Miriam Kaunanele Bernard1Department of Internal Medicine, Intermediate Hospital Oshakati, Oshakati, NamibiaDepartment of Internal Medicine, Intermediate Hospital Oshakati, Oshakati, NamibiaObjectives. To describe the clinical characteristics of patients presenting with fulminant liver failure after varying periods of exposure to Efavirenz containing antiretroviral medications. Methods. We report a series of 4 patients with human immunodeficiency virus (HIV) infection who were admitted with acute liver failure (ALF) over a 6-month period. All these patients had been treated with a range of Efavirenz containing antiretroviral regimens and were negative for hepatitis A, B, and C infections as well as other opportunistic infections, all were negative for autoimmune hepatitis, and none had evidence of chronic liver disease or use of alcohol or herbal medications. Information on patient clinical characteristics, current antiretroviral regimen, CD4 count, HIV-1 RNA levels, and clinical chemistry parameters was collected. Informed consent was provided. Results. During a 6-month period, four patients without other known risk factors for acute hepatitis presented with symptomatic drug-induced liver injury with varying symptoms and outcomes. The pattern of liver injury was hepatocellular for all the 4 cases. Liver biopsies were done for all the four cases and the results showed a heavy mixed inflammatory cell infiltrate with eosinophils. For three patients withdrawal of Efavirenz from their antiretroviral regimen was sufficient to restore transaminase levels to normal and led to improvement of clinical symptoms. For one patient his clinical course was characterized by fulminant liver failure and fluctuating episodes of hepatic encephalopathy which ultimately resulted in his death. Conclusion. Hepatotoxicity of Efavirenz is not as rare as previously described in the literature and does actually present with fatal outcomes. The key message to note is that frequent monitoring of liver enzymes should be done at initiation of antiretroviral therapy and should continue throughout the treatment period.http://dx.doi.org/10.1155/2018/1270716
spellingShingle Innocent Lule Segamwenge
Miriam Kaunanele Bernard
Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
Case Reports in Hepatology
title Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
title_full Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
title_fullStr Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
title_full_unstemmed Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
title_short Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
title_sort acute liver failure among patients on efavirenz based antiretroviral therapy
url http://dx.doi.org/10.1155/2018/1270716
work_keys_str_mv AT innocentlulesegamwenge acuteliverfailureamongpatientsonefavirenzbasedantiretroviraltherapy
AT miriamkaunanelebernard acuteliverfailureamongpatientsonefavirenzbasedantiretroviraltherapy